NewsEvents

Your Yourlocation: Home > Observation on the therapeutic effect of combined tiotropium bromide(136310-93-5) and budesonide suspension on COPD

Objective: To observe the effects of combined inhalation of tiotropium bromide(136310-93-5) and budesonide suspension on COPD. Methods: Sixty patients with COPD were enrolled in this study. Twenty patients (42 males and 18 females) were divided into three groups according to random number table: (1) 20 cases were treated with tiotropium bromide(136310-93-5) powder (1μg) , a single dose of dry powder inhaler, morning 1, inhaled budesonide suspension, through the DRT small atomizer, the dose of 1 mg each time, 2 times a day. (2) Budesonide inhalation inhalation group, 20 cases, inhaled budesonide suspension, the dose of 1 mg, 1 day 2 times. (3) Blank control group of 20 cases, treatment for 2 weeks. Results: FEV1 before inhalation of salbutamol was significantly higher in the test group than in the blank control group, and continued to the second week. The FEV1 level in the combination group was significantly higher than that in the budesonide group. At the end of the experiment, FEV1 increased 10.3% in the combination group and 8.2% in the budesonide group. The blank control group changed significantly. The difference was statistically significant. Conclusion: Inhalation of long - term anticholinergic drugs combined with long - acting hormone preparation for the treatment of COPD, in the control of symptoms, improve lung function are better than the use of hormones alone, and blank control group. The test did not find any more adverse reactions, the safety can be accepted.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved